| Recruiting | Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Ot NCT07227415 | Pfizer | Phase 1 / Phase 2 |
| Completed | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malig NCT03229278 | Rutgers, The State University of New Jersey | Phase 1 |
| Active Not Recruiting | Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer NCT03092856 | University of Southern California | Phase 2 |
| Completed | Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer NCT02899078 | University of California, Davis | Phase 1 / Phase 2 |
| Completed | Combination of Cryosurgery and NK Immunotherapy for Advanced Kidney Cancer NCT02843607 | Fuda Cancer Hospital, Guangzhou | Phase 1 / Phase 2 |
| Completed | Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer NCT02626130 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Unknown | Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma NCT02689167 | Centre Hospitalier Universitaire de Besancon | Phase 2 |
| Completed | Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer NCT02579811 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma NCT02555748 | Institut Claudius Regaud | Phase 4 |
| Active Not Recruiting | Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer NCT02664883 | University of Southern California | — |
| Completed | 18F-FSPG PET/CT for Cancer Patients on Therapy NCT02599194 | Andrei Iagaru | Phase 2 |
| Terminated | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer NCT02542202 | University of Chicago | N/A |
| Completed | Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, NCT02318771 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 |
| Completed | Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma NCT01926990 | Stanford University | — |
| Terminated | Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer NCT02089334 | Rexahn Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Completed | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer NCT01767636 | Mayo Clinic | Phase 2 |
| Completed | A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers NCT01743469 | Ipsen | Phase 2 |
| Completed | Radiotherapy As an Immunological Booster in Patients with Metastatic Melanoma or Renal Cell Carcinoma Treated NCT01884961 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 |
| Active Not Recruiting | Aerosolized Aldesleukin in Treating Patients With Lung Metastases NCT01590069 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors NCT01522820 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer NCT01462214 | Hans J. van der Vliet, MD, PhD | Phase 1 / Phase 2 |
| Completed | A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer NCT01829841 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Completed | Evaluation of Cognitive Function of Patients With Sunitinib or Sorafenib NCT01246843 | Radboud University Medical Center | — |
| Completed | A Phase 1b Trial in Patients With Renal Cell Cancer NCT01258348 | Eli Lilly and Company | Phase 1 |
| Terminated | Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer NCT00670748 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. NCT00428220 | Pfizer | N/A |
| Completed | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Tr NCT00027820 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| No Longer Available | Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Fai NCT00655252 | Novartis Pharmaceuticals | — |